Azathioprine in ulcerative colitis. by Jewell, D, Truelove, S

Risks and benefits of azathioprine therapy. by McGovern, D, Jewell, D

Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. by Jewell, D, Truelove, S

“…The attack was treated with a standard course of corticosteroids and the patients were immediately placed on treatment with either azathioprine in a dose of 2.5 mg/kg body weight or dummy tablets. …”

Azathioprine in ulcerative colitis: an interim report on a controlled therapeutic trial. by Jewell, D, Truelove, S

“…This interim report on a controlled therapeutic trial of azathioprine in ulcerative colitis deals with the first 40 patients to complete a one-year period of maintenance treatment with azathioprine or with dummy tablets. …”

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. by Fraser, A, Orchard, T, Jewell, D

“… BACKGROUND: There are limited data on factors predicting response to azathioprine and uncertainty regarding the optimal duration of treatment. …”

Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. by Fraser, A, Orchard, T, Robinson, E, Jewell, D

“…The mean total duration of azathioprine use was 27 months. The mean follow-up from diagnosis was 13.7 years and the mean follow-up from the start of azathioprine treatment was 6.9 years. …”

Immunosuppression in the treatment of inflammatory bowel disease. II. The effects of azathioprine on lymphoid cell populations in a double blind trial in ulcerative colitis. by Campbell, A, Skinner, J, Maclennan, I, Hersey, P, Waller, C, Wood, J, Jewell, D, Truelove, S

“…Blood lymphocytes and rectal plasma cells have been studied in patients with ulcerative colitis taking part in a double-blind trial of treatment with azathioprine. Treatment for 1 year resulted in a modest fall in blood lymphocyte count, with little change in neutrophils or platelets. …”

Oral methotrexate in ulcerative colitis. by Cummings, JR, Herrlinger, K, Travis, S, Gorard, D, McIntyre, A, Jewell, D

“…Indications for methotrexate in ulcerative colitis alone were azathioprine intolerance (31 of 42) and lack of benefit from azathioprine (11 of 42). …”

Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. by Herrlinger, K, Jewell, D

“…RESULTS: Recent pharmacogenetic studies have mainly focussed on immunosuppressive agents including corticosteroids, azathioprine, methotrexate and infliximab. Several polymorphic genes encoding enzymes involved in the metabolism of these drugs have been identified including the inosine triphosphate pyrophosphatase in thiopurine therapy, the methylene tetrahydrofolate reductase in methotrexate therapy and polymorphisms in apoptosis genes in infliximab therapy. …”

The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. by Fraser, A, Morton, D, McGovern, D, Travis, S, Jewell, D

“…BACKGROUND: The management of patients with inflammatory bowel disease who are resistant to or intolerant of azathioprine remains a challenge. Low-dose methotrexate has been shown to be effective in inducing remission in Crohn's disease. …”

Long-term outcome after admission for acute severe ulcerative colitis in Oxford: the 1992-1993 cohort. by Bojic, D, Radojicic, Z, Nedeljkovic-Protic, M, Al-Ali, M, Jewell, D, Travis, S

“…CONCLUSIONS: One week after admission with ASC in the prebiologic era, IRs had a 50% chance of colectomy within a year and 70% within 5 years, despite cyclosporin and azathioprine where appropriate. The maximum duration of remission in CRs was almost 5 times longer than IRs. …”